Ieq Capital LLC bought a new position in ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 20,502 shares of the biotechnology company's stock, valued at approximately $352,000.
Other hedge funds and other institutional investors also recently bought and sold shares of the company. Hollencrest Capital Management purchased a new position in shares of ADMA Biologics in the 3rd quarter valued at $30,000. Larson Financial Group LLC bought a new stake in shares of ADMA Biologics in the 3rd quarter valued at about $31,000. GAMMA Investing LLC grew its position in shares of ADMA Biologics by 106.6% in the 4th quarter. GAMMA Investing LLC now owns 1,874 shares of the biotechnology company's stock worth $32,000 after buying an additional 967 shares during the last quarter. National Bank of Canada FI purchased a new stake in ADMA Biologics during the third quarter valued at approximately $35,000. Finally, Harvest Fund Management Co. Ltd acquired a new position in shares of ADMA Biologics during the third quarter worth $62,000. Institutional investors own 75.68% of the company's stock.
ADMA Biologics Stock Performance
ADMA Biologics stock traded down $0.52 during midday trading on Monday, hitting $15.87. 2,953,128 shares of the company were exchanged, compared to its average volume of 2,284,203. The business has a fifty day simple moving average of $16.73 and a two-hundred day simple moving average of $17.99. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.26 and a current ratio of 7.09. The firm has a market capitalization of $3.75 billion, a PE ratio of 56.66 and a beta of 0.75. ADMA Biologics, Inc. has a fifty-two week low of $5.52 and a fifty-two week high of $23.64.
Analyst Ratings Changes
Several equities research analysts have weighed in on ADMA shares. Raymond James raised their price target on ADMA Biologics from $18.00 to $25.00 and gave the stock a "strong-buy" rating in a report on Friday, November 8th. HC Wainwright upped their target price on ADMA Biologics from $18.00 to $26.00 and gave the company a "buy" rating in a research report on Friday, November 8th.
Read Our Latest Research Report on ADMA Biologics
ADMA Biologics Company Profile
(
Free Report)
ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.
See Also
Before you consider ADMA Biologics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ADMA Biologics wasn't on the list.
While ADMA Biologics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
